meanwhile celgene owns more they can snatch up. they have what seems like an astronomical $84 billion valuation. but, and this is the huge but, they should f earn more than $6.50 a share, maybe seven. it's selling at just 17 times 2016 earnings? that's cheaper than clorox. crazy cheap. i have come back and said that big buyers are probably kicking the tires on these little bio te techs that some people are shorting every day to see if they have any promising drugs. if you short them because dick fisher comes on and says the fed has it all wrong you will be crushed. finally tech itself. totally bogus. the only teches are dirt cheap. hewlett-packard is cheap. microsoft with a big buy back. 16 times earnings? i don't think it's the least vulnerable. how about the internet stocks, every research firm rolled out alibaba today. it sells less than earnings estimates. i think the estimates are too low. any stock less than it's growth rate is too cheap. that's how the stocks rallied from the '70s. alibaba is a chinese company. you can happi

we have celgene and isis.think that is too risky to have both even though we know we like isis but we put isis on hold and keep celgene. we have pnc which is a fine bank. we have mobileeye in new cadillacs. cheniere moved up too much. the whole lng group is going down. that hasn't gone down enough. that is probably going to go lower. i want to switch it out and put in -- we have technology and a bank. we are going to stick with united technologies. that would be the industrial this portfolio needs. if isis comes out let's give it i'm thinking i want to have something so rock solid. what you need here is an american electric power. i need something so grounded. dominion resources to give you the kick of cheniere because they have natural gas plant that will be exporting. these things are not easy particularly when there is so much speculation out there and the speculation bubble has clearly -- your customers, our financing. your aspirations, our analytics. your goals, our technology. introducing synchrony finan

among those those, reagain ron, amgen and celgene, and facebook up 2.5%, apple up near 2%. kate. >> thank you so much. >>> let's look at the metals market. last trade on gold probably not surprising that we have a sell-o sell-off, because we have such a big move in equities. silver, copper, platinum and palladium. you can see the copper mark is up, so is palladium, an the platinum market giving back a little strength today, off about 1% or so. to the bond market, checking in on interest rates and currencies, rick santelli tracking action. ricky, over to you. wow, what a run it's been, you realize we are now, what, 44 basis points off a week ago wednesday 186 intraday low? , just a whisper under 230, up eight basis points on the day as you sea this 24-hour chart. if you open up the chart to early october, 10s haven't been here for about two weeks. the dax, like all over equities got its footing today, moved right through 9,000. you can see it here on the may 1st chart. the last chart, see, was talking about foreign exchange. this is september starts. it's had a rocket move.

celgene had had the flagship anti-blood cancer drug up 19%.was a breathtaking quarter with fabulous commentary about the success of some of the company's new cancer drugs that i didn't even know about right on top of some encouraging news about the breakthrough crohn's disease. rallying $5.64 as it plowed through $100 a share. it also cost the rest of the biotechs to roar especially regeneron which hit a new all-time high. diamond offshore, symbol d.o., and i don't talk about it much. this cohort of offshore drilling companies has been in its own personal horrendous bear market. for one of the weakest players delivering an upside surprise that aloud the heavily shorted group to bottom. it looks like brazil is about to go full board of drilling, i didn't know that, and it may not be just a glint in the eye of the bear's beholder. fifth, lots of people expected 3m to blow up because of the heavy exposure to overseas markets and the weakening international jog raves guaranteed a disappointment, i mean, didn't they? oops! didn't happen. as a matte

google, celgene, facebook and underarmour, they cannot run slow growth worldwide.he beers in particular, more on that later. here's the bottom line. i don't want to get carried away here, but i do think if you haven't committed any capital yet the time may be at hand. there are plenty of babies. i've given you them from being sucked down the drain at 11:43 a.m. when the legendary and brilliant hedge fund managers could no longer take the pain. >> savino in texas, savino. >> boo-yah, jimbo. mastercard is on my shopping list and i wish it was still longer for a pullback. >> sandler o'neal and the mastercard has put a chill in the situation. i don't want to have numbers coming down and i don't need real doubters in here. m.a., right now is on the hold list and not the buy list. how about doug in florida. doug? >> hi, jim. thank you for taking my call. >> of course. >> long time follower, first-time caller. i have a question about sienna corporation. it was recommended a while back and i've been watching it go down. i got stocked out of other stocks that turned around

this is the anti-celgene. lyric af lyrica. not that they didn't spend a lot of money on r&d. $1.8 billion in the course. >> you want r&d spend you go to david pyle who was on "mad money" last night. allergan under attack. if you spend that much money on r&d, i want to see new drugs. merck, there is nothing to write home in that one either. you go over celgene. just creating drugs by the day. i want companies that grow. >> while we are at it, and we'll get to this, sanofi shares are going to be down. >> fierce pharma, here is the headline, don't fire me. david, don't fire me. don't fire me. >> they are citing competition in the diabetes market. he potentially was attempting to sell them mature drugs which they are no longer doing and seemed to have run afoul. >> diabetes. is this "don't fire me" the same conversation rex ryan is having right now with woody johnson? >> i don't know. probably. >> don't you think this is embarrassing? i like him. he's been on the show. don't fire me approach has this, maybe i shouldn't buy that st

. >> celgene? >> monster. folks playing at home, it's a u in the middle. b-u-y. report add great quarter. a monster drug. a tremendous balance sheet. cash flow, major phrma would die for. trades at 21 times forward earnings which isn't crazy. bs put it on focus one list. 112 price target probably low. b-u-y. >> for you, too. >> all wait. >>> watch out meg whitman. strategist saying ready for them to enter the printing space. that's next. >>> plus, pete najarian down there, spotted unusual call volume in one stock. whether or not you should jump in, straight ahead. getting in a groove. growth is gratifying. goal is to grow. gotta get greater growth. i just talked to ups. they got expert advise, special discounts, new technologies. like smart pick ups. they'll only show up when you print a label and it's automatic. we save time and money. time? money? time and money. awesome. awesome! awesome! awesome! awesome! (all) awesome! i love logistics. an unprecedented program arting busithat partners businesses with universities across the state. for better access to talen

we talked about celgen in the green room, another all-time high. yahoo! feels like it wants to go to 45. amazon will have a tradeable bottom. we have j.j. flash to talk about that. >> pete najarian? >> i agree with guy. a little bit of a surprise how fast the snap back game. when the earnings are coming out, when you go through what the earnings have been over the last week or so, the good earnings they sold them off anyway. a lot of that was ebola. when we saw the oil really dragging down the market, that pulled down some of the good stocks as well. created opportunities. whether it was in the airlines or even in the financials. look at the turn we got out of goldman sachs from last week trading at the near 170 level and now at 183 again. the pops we've gotten out of these have been fast, faster than anybody expected. volatility has come down less than a half. >> what were you buying then? >> in the last couple of four or five trading session, goldman sachs, morgan stanley, bank of america, citi, then in the airline doubling up and tripling up on some of

celgene, biogen. >> this is the doctors without border. they know how to do it.g the military getting in it. i think that is very important. >> it's only been a week since the latest new case. amazing what you can do. >> 317 million people so far have not contracted ebola. i find that number comforting. >> indeed. >> it's not the mass panic. >> carnival is on the list. >> yeah. the airlines. they seemed like layup shorts. a lot of people are saying delta reported a good quarter. fuel costs are down a lot. people will be traveling again. that's the short of caving, recognizing they made this call that perhaps this weekend many people are going to come down with ebola. anybody near the late mr. duncan had to have contracted it, and it must be a little more difficult to contract. >> thankfully that would seem to be the case. i want to mention time warner. i've been watching this stock go up, up, up, after last week when they introduced their guidance. very significant numbers and over the top hbo, which they haven't rolled out. no a lot of details around it. that st

for their best call it an earnings-led rally today, certainly what it's been, 3m, caller pillar, celgene, and that spurred stocks right from the get-go. bob pisani, that's been the story, better earnings, things feeling a bit better, and the stock market taking off again today. >> i want to list a few other factors. scott is right, earnings were better than expected. i also want to point on the that hedge funds have been selling aggressively have been getting forced back in. we're getting into a seasonal strong time of year. oil is up vgts that's another factor. china manufacturing numbers, i think they're the margins that matter, and of course that terrible incident in canada appears to be the work of a lone wolf. psychologically that may be plays into into it. we're getting etfs, have very heavy volumes. look at the vti. this is everything. very notable voc here today. when you get that kind of tiismt, it means people are trying to buy the whole market. a 3m, caller pillar. caller pillar beat by 36 seconds, that's a remarkable beat important thing here, most of the beat was in the ener

the red, the nasdaq recovering somewhat but the biggest loser of the bunch off its lows but tesla, celgene about the biggest losers follows a tough week for that index and markets. let's bring in contributor rich bernstein, ceo of richard bernstein advisors. good to have you with us. is this about the semiconductor still? >> well, kelly, i think you could point depends on where you want to look in the market you could point to about anything, whether something in technology or something in europe or something in commodities. i mean i think for anybody who wants to be bearish there's plenty of fodder to chew on. >> how much further does this correction and how much deeper do you think it goes then, rich? >> that's the ten cent question. i wish i was that smart. i'm the worst short-term trader. they never invite me on "fast money" but i will say, look whenever you have a correction, one has to sit and try to decide is there something fund mentally deteriorating in the economy and corporate profits or is this a buying opportunity. and i think when we look at the data, we say this is much more

celgene. i divide them in secular growth mode. they are gigantic fires on commodity.arden is doing well, and i like jack. all these companies depend on one thing. i've got to put it out there i hate to do it. you want ebola contained. why do i say this? i go on twitter, my thesis and people from dallas are saying, jim, come down to dallas and you'll know you are not going to see that store traffic you think. that to me smacks of panic. that's the only wild card. otherwise this employment number fits perfectly with my thesis. you have to be long domestic. i am going to say that ebola is going to be under control. >> i think and hope that you are right. >> let's get back to this medtronic story. the stock is up sharply. medtronic up 4%. take a look at shares of covidien. the company put out a press release under which medtronic is changing its source of cash for the deal. originally, it was planning on using its overseas cash, $16 billion, to pay for part of the consideration in a deal that calls for it to pay $35.19 in cash and 0.96 of those shares for each share of co

we didn't mention celgene yet. that historically sold off when it reports.ir bread and butter plus 19. they have stakes in so many different companies. that's important. lam research did not raise the guide. there is a lot of belief here now. >> defense companies continue to knock it out of the park. lockheed is one of the winners. boeing is challenged. general dynamics, highest operating net in four years. highest margins in six years. >> i am disappointed in retrospect lockheed martin didn' didn't. northrop grubman is amazing. these are companies that saw it company and are doing a better job than people realized. >> caterpillar, $172 was a blowout. >> people figured caterpillar, that is a layup short. sometimes the market confounds you. you see 3m up four. people expected them to miss the quarter. when you expect to miss a quarter, stock goes from $148 to $138, analysts are getting negative, then you get a short squeeze. that is what's happening there. >> cat and 3m are the best performing dow components. at&t, obviously, the worst, followed by procter an

. >>> celgene. this company is amazing. the company sells at less than 20 times earnings.his is going right to $120 is my view, taking gilead with it. only $1 off the 52-week high. gilead was the controversial hep-c. regeneron should see 400 today. >> people want your view on bmy. >> bristol was -- what can i tell you? bristol-meyers, very fine quarter. they are doing a lot of things right. remains a core holding for every person who thinks what stock can i own the next five years? >> we never mentioned shire. >> that's our bad. shire had an unbelievable quarter. >> it did it is well off the lows when everybody sold it. when the abbvie deal broke. >> the hive $1.6 billion. >> not unlike biomarin. they do a lot of orphan drugs, a great business protected by patent. there's a lot -- these companies are doing great. they are going up because they are inventing things and discovering things and curing things. >> finally on the broader market, we are going to talk to mike santolli. you have a bull and bear in the ring. one pushes the other out of the ring and they reset. >> mas

celgene. do you think the ceo says, you know what? i'm worried about that guy plosser. there is a cleveland woman. do you think the guys at gilead are saying that cleveland fed whatever? do you think they sit there and say fisher told us we are done. do you think they say that at regeneron? it doesn't work like that in corporate america. they are making money for you as a shareholder because they are trying every day to beat everyone else. the competitors -- these guys are about making the playoffs. making the playoffs? this is a game, note practice. it is a game. i'm just saying i am upset because the ceos are giving it all she's got. what we tend to do is say, you know what? this is all about qe whatever. if you sit down with these ceos, we are killing it, man. talk about how we are killing it. talk about the innovation. talk about the discoveries. why don't you talk about the execution? why do you sit there and talk about the philly fed? >> let's talk about starbucks. >> sure. >> quarterly earnings in line with street estimates. revenue just shy of consensus. starbuc

amgen today strong and also its analyst day and new highs for cerner and celgene, as guerilla. >> tdade on move after new assets boosted the quarterly profits. also adding to the optimism, the forecast for next year where it could see further asset growth in 7% to 11%. >> joining us, ceo fred omaha. good to see you. thank you for joining us. >> great to be with you today. >> volatility. i'm guessing you like it. it's good for your business because you get more trading and all. the average investor i'm going to guess doesn't like it. how do you balance that to your customers out there? do you like the fact that you get the volatility of october or do you wish we'd go back to a slower growth stock market? >> you know, we've been saying for a while as we get through this the fed put a lot of stimulus into the system. and as they start to adjust that stimulus, you're going to see increased volatility and we are seeing that so far in october. we don't mind volatility in terms of trading levels as long as the trajectory on an upward trend over time and we don't have the big moves in the ma

keep track of celgene.e crohn's disease tease and, gee, an incredible anti- n pancreatic cancer drug. >> merck, by the way, 90 cents a share. a bit ahead of estimates. but the revenue number was shy of analysts who follow the company expecting. and it did narrow full-year earnings forecast patent expirations weighing on the company as well. that's why you're seeing that, gain na generics. >> micron. the innards of pcs, one of great untold stories microchip reported bad quarter and everybody fled, everybody company that had to do with semiconductors. i think people will compact and say pcs were very good. by the way, apple, 1, rite aid and cvs zero. >> why? >> apple can rule these companies. tim cook, visa, mastercard can rule these two outliers. >> why do you believe that? not a lot of people -- not a lot of retailers signed up for apple pay. >> who wants to lose customer who says, can i want? can i wand? now you have to put in your pin number, no, put it in again, oh, hold, there's a dollar for charity, ye